Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Feigh

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Frontiers in Bioscience (Scholar Edition)|December 29, 2009
Persistent low-grade inflammation and regular exerciseMaj-Briit Astrom, Michael Feigh, Bente Klarlund Pedersen
Plos One|April 25, 2024
Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitisLuciano Adorini, Kristoffer Rigbolt, Michael Feigh, et al.
International Journal of Molecular Sciences|July 2, 2021
Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASHNikolaos Perakakis, Pavlina Chrysafi, Michael Feigh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 31, 2021
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitisNikolaos Perakakis, Konstantinos Stefanakis, Michael Feigh, et al.
Scientific Reports|April 24, 2022
Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitisJohn J Nestor, David Parkes, Michael Feigh, et al.
British Journal of Pharmacology|March 3, 2021
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosisAimo Kannt, Paulus Wohlfart, Andreas Nygaard Madsen, et al.
Drug Discovery Today|July 9, 2017
Mouse models of nonalcoholic steatohepatitis in preclinical drug developmentHenrik H Hansen, Michael Feigh, Sanne S Veidal, et al.
Npj Metabolic Health and Disease|July 3, 2025
FGF21 deletion mildly exacerbates hepatic dysfunction in GAN diet and alcohol fed ratsPeter Aldiss, Malte Hasle Nielsen, Hayley Burm, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|February 28, 2023
Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitisMalte Hasle Nielsen, Matthew P Gillum, Niels Vrang, et al.
Menopause (New York, N.Y.)|June 25, 2013
Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in ratsMichael Feigh, Kim V Andreassen, Sara T Hjuler, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Frontiers in Bioscience (Scholar Edition)|December 29, 2009
Persistent low-grade inflammation and regular exerciseMaj-Briit Astrom, Michael Feigh, Bente Klarlund Pedersen
Plos One|April 25, 2024
Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitisLuciano Adorini, Kristoffer Rigbolt, Michael Feigh, et al.
International Journal of Molecular Sciences|July 2, 2021
Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASHNikolaos Perakakis, Pavlina Chrysafi, Michael Feigh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 31, 2021
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitisNikolaos Perakakis, Konstantinos Stefanakis, Michael Feigh, et al.
Scientific Reports|April 24, 2022
Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitisJohn J Nestor, David Parkes, Michael Feigh, et al.
British Journal of Pharmacology|March 3, 2021
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosisAimo Kannt, Paulus Wohlfart, Andreas Nygaard Madsen, et al.
Drug Discovery Today|July 9, 2017
Mouse models of nonalcoholic steatohepatitis in preclinical drug developmentHenrik H Hansen, Michael Feigh, Sanne S Veidal, et al.
Npj Metabolic Health and Disease|July 3, 2025
FGF21 deletion mildly exacerbates hepatic dysfunction in GAN diet and alcohol fed ratsPeter Aldiss, Malte Hasle Nielsen, Hayley Burm, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|February 28, 2023
Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitisMalte Hasle Nielsen, Matthew P Gillum, Niels Vrang, et al.
Menopause (New York, N.Y.)|June 25, 2013
Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in ratsMichael Feigh, Kim V Andreassen, Sara T Hjuler, et al.
Pageof 5